Back to Journals » The Application of Clinical Genetics » Volume 12

Adverse Drug Reactions Associated with CYP 2B6 Polymorphisms in HIV/AIDS-Treated Patients in Yaoundé, Cameroon

Authors Nguefeu Nkenfou C, Atogho Tiedeu B, Nguefeu Nkenfou C, Nji AM, Chedjou JP, Tah Fomboh C, Kouanfack C, Mbacham WF

Received 7 August 2019

Accepted for publication 23 November 2019

Published 30 December 2019 Volume 2019:12 Pages 261—268

DOI https://doi.org/10.2147/TACG.S226318

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Martin H. Maurer


Carine Nguefeu Nkenfou,1,2 Barbara Atogho Tiedeu,1,2 Celine Nguefeu Nkenfou,3–5 Akindeh M Nji,1,2 Jean Paul Chedjou,1,2 Calvino Tah Fomboh,2,6 Charles Kouanfack,7,8 Wilfred F Mbacham1,2,9

1Department of Biochemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon; 2The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon; 3Systems Biology, Chantal Biya’ International Reference Centre for Research on HIV and AIDS Prevention and Management (CBIRC), Yaoundé, Cameroon; 4Department of Biology, Higher Teachers’ Training College, University of Yaoundé I, Yaoundé, Cameroon; 5Molecular Biology Center Yaoundé, Yaoundé, Cameroon; 6Catholic University of Yaoundé (UCAC), Yaoundé, Cameroon; 7Day Care Unit, Central Hospital Yaoundé, Yaoundé, Cameroon; 8Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon; 9Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon

Correspondence: Wilfred F Mbacham
Laboratory for Public Health Research Biotechnologies, Biotechnology Center (BTC), P.O. Box 3851, Nkolbisson, Yaounde, Cameroon
Tel +237-677579180
Email wfmbacham@yahoo.com

Purpose: The metabolism of antiretroviral drugs is subject to individual variations of the CYP 2B6 gene. The objective of this study was to evaluate the prevalence of CYP 2B6 516 G>T and 983 T>C polymorphisms and investigate their association with the development of adverse drug reactions (ADRs) in people living with HIV/AIDS in Cameroon.
Patients and methods: A total number of 122 patients, attending the Yaoundé Central Hospital HIV Day Clinic, consented to take part in this study. Blood specimens were collected and DNA was extracted using the Chelex method. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was performed for the detection of CYP 2B6 Single-Nucleotide Polymorphisms (SNPs). Genotype frequencies were compared between groups with or without ADRs. Logistic regression analysis was performed to assess association between genotype and adverse effects of antiretroviral therapy (ART).
Results: Three types of metabolizers were identified: extensive, intermediate and slow. For the 516G>T polymorphism, prevalences of 8.2% GG, 65.6% GT and 26.2% TT were obtained. For the 983T>C polymorphism, 89.3% TT, 4.1% CT and 6.6% CC prevalences were obtained. Those homozygous for the wild-type allele (516GG) were less likely to develop ADR with a statistically significant difference (OR=0.885, P=0.029). For the CYP2B6 T983C SNP, homozygous mutants (CC) may present a higher risk (threefold) of developing adverse reactions (OR=2.677, P=0.164).
Conclusion: These findings demonstrate that ADRs among HIV/AIDS patients under ART may be associated with the genetic variability of the metabolizing enzyme CYP 2B6. Genotyping for this gene may guide the better administration of Efavirenz and Nevirapine to Cameroonian patients.

Keywords: CYP 2B6 polymorphisms, association, adverse drug reactions, HIV/AIDS


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]